ANN ARBOR, Mich., April 30, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, honors Arbor Day by funding the planting of more than 100,000 mulberry trees.   While playing a vital role in purifying our air and stabilizing the soil, these trees also serve as a valuable, sustainable resource for the production of the Company’s proprietary spider silk technology.

The Company believes that in pledging to do what is right for the environment, it can strengthen its business and expand future opportunities. Kraig Labs’ business model is built on the utilization of renewable and sustainable mulberry leaves for the production of recombinant spider silk. Under the care of Prodigy Textiles, the Company’s Vietnamese subsidiary, these trees are already supporting production operations and will continue to play a significant role in the commercialization of Company’s recombinant spider silk technologies.

“Through thoughtful design of our production systems, with an eye towards energy efficiency, a reduction in inorganic materials, and a low carbon footprint, we created a system that is in line with long honored cultural traditions, where eco-responsibly is a valuable byproduct of doing what is best for our business and our shareholders,” said Jon Rice, COO. “I am proud of the work our team has done to contribute to the more than two million acres of mulberry trees planted globally, as part of our efforts to bring materials of unparalleled performance to the textile markets.”

To view the most recent news from Kraig Labs, including recent mulberry tree pictures at one of its co-op tree farms, and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., April 22, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that Spydasilk Enterprises Pte. Ltd. (“Spydasilk Enterprises”), the Company’s Singapore based joint venture, with M the Movement and Kings Golden Harvest Pte Ltd (collectively, “Kings Group”), has applied for its first four Spydasilk brand trademarks with the US Patent and Trademark office.

These first four trademarks include brand and product specific marking that Spydasilk Enterprises will use in the branding and marketing of its yarns, textiles, and finished garments.

“Our goal was to design the Spydasilk trademarks to be clean, distinctive, and powerful, able to stand alone or work in collaboration with co-branding opportunities with potential product partners. I think that our design team delivered on all four of these criteria, creating a memorable brand with the unique inspired design,” said Walter Wee, CIO of Kings Group.

In addition to Spydasilk Enterprises developing a premium apparel, based on Kraig Labs’ spider silk technologies, Kraig Labs and Kings Group are simultaneously building other spider silk sales markets outside of apparel and textiles. With that in mind, the companies are working quickly to build Spydasilk Enterprises’ down channel distribution network. These additional markets are expected to further expand the previously announced exclusive purchase and sales agreement, valued at up to US$40 million.

“SpydaSilk is obviously a unique enterprise, so we wanted to create trademarks that highlight the technology at the center of the brand. These trademarks provide distinctive styling that will help our customers easily identify Spydasilk’s product and the performance driven technologies at the heart of their design,” said Kim Thompson, Kraig Labs’ founder and CEO.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kings Group and M the Movement

Kings Group is headquartered in Singapore and established regional offices with multiple assets in Indonesia and Vietnam. Kings Group envisions itself to be a forerunner in International Marketing and Trading; bridging domestic businesses and projecting their products internationally.

For further information, please visit www.kings.com.sg.

M the Movement is Kings Group’s premiere eco-friendly luxury streetwear line. Internationally recognized and loved by celebrities globally.

For more information, please visit www.mthemovement.com 

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., April 09, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company, together with M the Movement, Kings Golden Harvest Pte Ltd (“Kings Group”), has established Spydasilk Enterprises Pte. Ltd. (“Spydasilk Enterprises”) as a Singapore based joint venture.

This partnership represents the Company’s first vertically integrated sales channel.

Spydasilk Enterprises is developing a premium line of luxury streetwear based on Kraig Labs’ spider silk technologies with exclusive sales rights within the Association of Southeast Asian Nations (ASEAN) region. The move positions Kraig Labs and Kings Group to advance their partnership, which began with a previously announced exclusive purchase and sales agreement valued at up to US$40 million.

“Based on our initial efforts, there is a definite demand for spider silk technology and product developers are very excited about working with these super fibers,” said Walter Wee, CIO of Kings Group. “In addition to building up the Spydasilk brand, we must build Spydasilk’s vendor and customer bases. We are already having great success with clients that share our vision and passion for spider silk. We believe that their efforts will further broaden Spydasilk’s market opportunities in multiple industries asides from the fashion industry,” continued Wee.

The new joint venture company will commercialize Kraig Labs’ biodegradable and biocompatible ‘super fibers’, using a scalable and cost-effective spider silk production platform and patented spider silk gene sequences in silkworms.

“This new joint venture is the beginning of the fulfillment of my original vision for Kraig Labs, where we are able to vertically integrate and capture intermediate and end product margins. Thanks to Walter and the Kings Group team, Spydasilk should hit the ground running. We have high expectations for the future of spider silk and Spydasilk Enterprises,” said Kim Thompson, Kraig Labs’ founder and CEO.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kings Group and M the Movement

Kings Group is headquartered in Singapore and established regional offices with multiple assets in Indonesia and Vietnam. Kings Group envisions itself to be a forerunner in International Marketing and Trading; bridging domestic businesses and projecting their products internationally.

For further information, please visit www.kings.com.sg.

M the Movement is Kings Group’s premiere eco-friendly luxury streetwear line. Internationally recognized and loved by celebrities globally.

For more information, please visit www.mthemovement.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., March 26, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $4 million dollars of expansion capital. This financing significantly strengthens the Company’s balance sheet and supports its progress in the commercialization and sale of recombinant spider silk.

“This is a major financial milestone for Kraig. For many years we have operated on a shoestring budget, building a solid foundation with our spider silk production system. We are now prepared to reap the rewards of that careful investment with opportunities to put this capital to work building materials, products and brands,” said CEO and Founder, Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., March 15, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Vietnamese patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig . This patent plays a vital role in Kraig’s growing portfolio of spider silk Intellectual Property. The Company’s recombinant spider silk production is headquartered in central Vietnam.

Patent number 26612, titled “A Chimeric Spider Silk Polypeptide, Composite Fiber Comprising the Polypeptide and Method of Making a Chimeric Spider Fiber” was issued to the University of Notre Dame (UND) under the Company’s exclusive license agreement. Under the terms of that agreement, the Company paid for the development of the technology and the costs of patents issued to UND in exchange for exclusive global licensing rights. This patent provides protection for the Company’s proprietary recombinant spider silk through September of 2031.

With today’s announcement, the Company now expands protection for its spider silk technologies to include; Australia, South Korea, Canada, and Vietnam, with numerous other applications in other jurisdictions under review.

“Recognition by the Vietnamese government of our specialized spider silk technologies opens new doors and opportunities for production expansion within Vietnam. Congratulations are in order for the researchers at the University of Notre Dame and Kraig for the breakthroughs that led to this patent. I would also offer a special thanks to our counsel at Workmann Nydegger, who have done an excellent job of spearheading Kraig’s IP filings,” said COO Jon Rice. “Our team at Kraig continues to prove that our vision for a cost-effective and environmentally responsible system for the mass commercialization of spider silk is now a reality.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., March 10, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has doubled its planned production volumes of its recombinant spider silk for the month of March.

Following the successful delivery of its first sample production run from its factory in Vietnam, the Company has further accelerated its expansion by doubling planned near-term silk output. To support this expansion, the Company has outlined plans to more than double the staff at its Prodigy Textiles subsidiary.

The silk resulting from this month’s operations is expected to begin filling existing material requests and contract deliverables to M the Movement, PL Kings. The Company is actively working now to develop the first line of apparel based on the unique properties of spider silk.

“Last month our team at Prodigy Textiles set the stage with the delivery of the first production samples of our recombinant spider silk. This month that team is delivering on the promise of a cost-effective and commercially scalable spider silk production system,” said COO Jon Rice. “I am very excited for the opportunities ahead for Kraig as we prepare to bring our spider silk to market.”

The Company seized the opportunity to expand near-term production of its eco-friendly spider silk when it was able to secure additional production inputs.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include the planned production of Spider Silk, future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., March 02, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Canadian patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig. This patent further protects Kraig’s growing portfolio of spider silk Intellectual Property.

Patent number 2,812,791, titled “Chimeric Spider Silk and Uses Thereof” was issued to the University of Notre Dame (UND) under the Company’s exclusive license agreement. Under the terms of that agreement, the Company paid for the development of the technology and the costs of patents issued to UND in exchange for exclusive global licensing rights. This patent provides protection for the Company’s proprietary recombinant spider silk through September of 2031.

“Congratulations to both the researchers at the University of Notre Dame and Kraig’s science team. Kraig Labs plans to continue building upon and protecting our position as a leading biomimicry company. This patent is an important step on the Company’s path to remaining the premier technology and fiber supplier in the spider silk space,” said Jon Rice, the Company’s Chief Operations Officer. “We’ve created multiple strains of high-performance spider silk fibers that we are excited about. Protecting our specialized materials in key end markets is a core component of our commercialization efforts.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Feb. 23, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company received its first small shipment of spider silk from Prodigy textiles, its wholly-owned Vietnamese subsidiary.

The Company has received fiber requests from a broad range of interested parties, including companies that produce products in the fields of sports apparel, industrial textiles, first responder supplies, medical products, and other manufacturers. In order to meet this demand, the Company established Prodigy Textiles to scale up the production of its recombinant spider silk fibers, threads, and textiles.

The Company’s operations at its Prodigy Textiles facility are now moving forward to significantly expand the Company’s spider silk production. The Company expects to begin filling the backlog of material requests, including requests from Polartec LLC and MtheMovement, as this added capacity comes online.

“I want to thank the Prodigy Textiles team for making this milestone possible and setting the stage for our expansion. This helps us transition from being the leading developer of spider silk technologies to the producer and supplier of high quality spider silk fibers,” said Jon Rice, the Company’s Chief Operations Officer. “Now we can focus on meeting the substantial demand for spider silk and solidifying market channel partnerships to reach our goal to develop and bring new products to market.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Feb. 16, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has filed a patent application protecting its most advanced knock-in knock-out gene editing technologies for the creation of nearly pure spider silk.

Entitled “Modification of Heavy Chain Fibrion in Bombyx Mori“, this patent covering the core technologies the Company has developed for the mass production of nearly pure spider silk fibers. Specifically, the Company has leveraged the application of knock-in knock-out technology to create the most genetically advanced and purest spider silk fibers in the Company’s history. The Company has also filed a corresponding patent application under the global Patent Cooperation Treaty process to protect these technologies internationally.

These technologies and inventions were first disclosed in a provisional patent filed with the United States Patent and Trademark Office (USPTO) under applications #62/995,717 on February 11, 2020. This full patent application, now filed, takes advantage of that earlier priority date in the USPTO’s first to file patent system. The Company made the discovery of this breakthrough public during a press conference held on April 16, 2020 where it reported the creation of this new technology with a spider silk purity nearly ten times greater than Dragon Silk, the Company’s previously developed recombinant spider silk fibers.

“Since first reporting the development of this new Knock-in, Knock-out gene-editing system, we have moved forward rapidly to bring this nearly pure spider silk to market. The filing of this full patent application is well-timed as we expect to begin transitioning this new, purer spider silk technology to our production facility in the near future,” said Kim Thompson, CEO and founder of Kraig Labs. “These technologies are core to the commercialization of spider silk, and we will continue to push forward aggressively to protect and grow intellectual property while we remain squarely focused on the commercialization and generating sales.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

ANN ARBOR, Mich., Jan. 26, 2021 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it is forming a joint venture partnership with MtheMovement, an eco-friendly luxury streetwear apparel line, part of the Kings Group of Companies and its affiliated companies (“Kings Group”).

The joint venture will develop and sell Kraig Labs’ spider silk fibers under the new innovative apparel and fashion brand, trade named SpydaSilk™ and potential other trademarks to be announced. All intellectual property related to SpydaSilk™ will be jointly owned by Kraig Labs and Kings Group. The deal combines Kraig Labs’ industry leading fibers with Kings Group’s business skills and regional enterprise expertise, creating what we believe will be a strong vertical integration for both companies.

Under the terms of this agreement, Kraig Labs granted the joint venture and the SpydaSilk brand an exclusive geographic license to all Kraig Lab technologies for the ASEAN region, in exchange for a 4 year firm commitment to purchase up to $32 million, with an additional projected purchase of $8 million, of Kraig Labs’ raw recombinant spider silk, with an initial payment of $250,000.

“SpydaSilk’s mission is to create high-impact products and technologies, so partnering with Kings Group, which we believe has strong product development expertise and intense understanding of ASEAN market, is a powerful combination that we believe will drive SpydaSilk’s sales and innovation,” said Kim Thompson, Kraig Labs’ founder and CEO. “Kraig Labs has always been proud to maintain our vanguard position in the spider silk space; this agreement strengthens our leadership role with a partner who shares our vision and places Kraig Labs and Kings Group on the best path for success. Spider silk is among the strongest fibers produced in nature, and the agreement represents the world’s first large-scale commitment to purchase spider silk fibers”

The new SpydaSilk alliance combines the strengths of both companies and calls on Kraig Labs to provide fibers and materials expertise, while Kings Group will lead the marketing, sales, and distribution. The two companies will work together to increase Kraig Labs’ product development agility and production scalability.

Under this collaboration, Kraig Labs and Kings Group believe that the material will not only be applied to apparel; the joint venture is also exploring uses to enhance other industries such as building construction and medical industries.

“Kings Group is dedicated to helping unleash the benefits of spider silk and this bold enterprise, the unveiling of the SpydaSilk^TM joint venture, significantly accelerates that goal. We believe that we will help improve the world through innovation to drive profitable growth, reduce emissions, enhance customer loyalty, and create long-term shareholder value,” said Mr. Walter Wee, Chief Investment Officer of Kings Group. “In researching various spider silk technologies, we came to the conclusion that Kraig Labs is the leader. Our agreement with Kraig Labs represents the first large-scale commitment to spider silk commercialization and we could not be happier to begin this part of our SpydaSilk™ journey.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kings Group and MtheMovement:

Kings Group is headquartered in Singapore and established regional offices in Indonesia and Vietnam. They have associate companies spread throughout Asia that have a dynamic synergy for maximizing resources and outreach to a huge consumer market. Kings Group is a forerunner in International Marketing and Innovative Product Trading; they specialize in bridging domestic businesses and projecting their products internationally.

For further information, please visit www.kings.com.sg, www.kingsglobalconsultants.com

MtheMovement is Kings Group’s premiere eco-friendly luxury streetwear line, for the past 20 years, they have been the leaders of fashion trends and have consulted designs with branding for many renowned corporates. Their Chief Creative Officer has also dressed many of the Grammy and Emmy Awards participants and famous international fashion celebrities.

For more information, please visit www.mthemovement.com

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com